Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
New research shows that PD1 can be potentiated by freeing up its ligand, PDL1, from binding to CD80, thereby improving symptoms of autoimmune disease in animal models.
proBDNF and its receptor are expressed in antibody-secreting cells in systemic lupus erythematosus, identifying a potential biomarker of disease activity and a therapeutic target.
New research shows that induction of ferroptosis can deplete synovial fibroblasts that are activated in rheumatoid arthritis, and that co-treatment with a TNF inhibitor enhances this depletion.
The COVID-19 pandemic has caused a rapid transition towards telemedicine, raising concerns about assessment accuracy, medical-relationship building and potential inequalities between patient groups. For some rheumatology patients, telemedicine is convenient and acceptable, but careful selection and choice are important.
Undifferentiated arthritis (UA) was redefined by the introduction of the 2010 rheumatoid arthritis (RA) classification criteria. But UA is more than just not having RA — it is about selecting the right patients for DMARD treatment even before diagnosis, and about protecting those with self-limiting disease from potential drug toxicity.
In this Review, the authors summarize the current knowledge relating to SARS-CoV-2 infection and the prevention and treatment of COVID-19 in people with rheumatic disease.
Axial spondyloarthritis, an immune-mediated inflammatory disease, is characterized by chronic back pain, joint stiffness and fatigue that can severely affect the quality of life. This Review summarizes the progress in the pharmacological management of this disease, including newly approved biologic DMARDs.
In this Review, Paggi et al. discuss the requirements and challenges in engineering a joint-on-chip device, propose an architecture for such a model of the joint and highlight the potential for these platforms to further advance insight into arthritic diseases and facilitate drug development.
Here, the authors describe the mechanisms that normally limit function and survival of activated T cells in peripheral tissues and discuss how defects in these processes can facilitate the development of chronic inflammatory responses that underlie organ damage in rheumatic autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis.
